|
| 非布司他治疗肾移植术后高尿酸血症的临床疗效及影响因素分析 |
| Clinical efficacy and influencing factors of febuxostat in treatment of hyperuricemia after renal transplantation |
| 投稿时间：2019-12-11 |
| DOI：10.3969/j.issn.1000-0399.2020.05.009 |
| 中文关键词: 非布司他 肾移植 高尿酸血症 移植肾存活率 |
| 英文关键词: Febuxostat Renal transplantation Hyperuricemia renal Kidney transplant survival rate |
| 基金项目: |
|
| 摘要点击次数: 1250 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的 探讨非布司他治疗肾移植后高尿酸血症的临床疗效、安全性及影响因素。方法 收集2017年4月至2019年4月在中国人民解放军联勤保障部队第九二四医院确诊的肾移植术后高尿酸血症患者164例。根据非布司他治疗后血尿酸水平，将患者分为达标患者（n=118）与未达标患者（n=46）。比较两组患者治疗前后的基本临床资料，并分析影响非布司他临床疗效的危险因素。结果 非布司他治疗后，患者血尿酸水平为（382.43±81.90）μmol/L、白细胞计数（WBC）为（6.36±2.10）×109/L、尿尿酸水平为（3.36±0.80）μmol/L，血红蛋白（Hb）为（123.64±18.73） g/L，与治疗前比较，差异均有统计学意义（P<0.05）。达标患者高血压（19.49%）、糖尿病（8.47%）、转换用药（2.54%）和用药间隔[（2.72±0.75）个月]与未达标患者比较，差异均有统计学意义（P<0.05）。高血压和转换用药是影响非布司他治疗肾移植术后高尿酸血症的危险因素，用药间隔为保护性因素（P<0.05）。结论 非布司他可显著降低肾移植术后的高尿酸水平，高血压和转换用药是影响非布司他临床疗效的危险因素，用药间隔为保护性因素。 |
| 英文摘要: |
| Objective To study the clinical efficacy, safety and influencing factors of febuxostat in the treatment of hyperuricemia after renal transplantation. Methods A total of 164 patients with hyperuricemia after renal transplantation diagnosed at the 924th Hospital of the Joint Support Force of the Chinese People's Liberation Army from April 2017 to April 2019 were collected.According to the serum uric acid level after treatment with febuxostat, the patients were divided into the standard group (n=118) and the non-standard group (n=46). The basic clinical data of the two groups of patients were compared before and after treatment, and the risk factors affecting the clinical efficacy of febuxostat were analysed. Results After febuxostat treatment,blood uric acid level (382.43±81.90) μmol/L,white blood cell count (WBC) (6.36±2.10)×109 /L, uric acid level (3.36±0.80) μmol/L, and hemoglobin (Hb) (123.64±18.73) g/L were markedly differentcompared with those before treatment(P<0.05).Compared with patients who failed to meet the standard, hypertension (19.49%), diabetes (8.47%), switching medication(2.54%) and medication interval[(2.72±0.75) months] were statistically significant (P<0.05). Hypertension and switching medications were risk factors affecting febuxostat in the treatment of hyperuricemia after renal transplantation, and the interval between medications was a protective factor (P<0.05).Conclusions Febuxostat can significantly reduce the high uric acid level after kidney transplantation. Hypertension and drug conversion are risk factors that affect the clinical efficacy of febuxostat, and the interval between medications is a protective factor. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
